DK2596010T3 - Signalbiomarkører - Google Patents

Signalbiomarkører Download PDF

Info

Publication number
DK2596010T3
DK2596010T3 DK11810311.8T DK11810311T DK2596010T3 DK 2596010 T3 DK2596010 T3 DK 2596010T3 DK 11810311 T DK11810311 T DK 11810311T DK 2596010 T3 DK2596010 T3 DK 2596010T3
Authority
DK
Denmark
Prior art keywords
cnpsp
fragment
level
eposp
antibody
Prior art date
Application number
DK11810311.8T
Other languages
English (en)
Inventor
Christopher Joseph Pemberton
Arthur Mark Richards
Original Assignee
Otago Innovation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otago Innovation Ltd filed Critical Otago Innovation Ltd
Application granted granted Critical
Publication of DK2596010T3 publication Critical patent/DK2596010T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G01N33/746—Erythropoetin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/505—Erythropoietin [EPO]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Brain natriuretic peptide [BNP, proBNP]; Cardionatrin; Cardiodilatin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/324—Coronary artery diseases, e.g. angina pectoris, myocardial infarction
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/325—Heart failure or cardiac arrest, e.g. cardiomyopathy, congestive heart failure
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/34—Genitourinary disorders
    • G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Claims (15)

1. Fremgangsmåde til forudsigelse, diagnosticering eller monitorering af en hjerteforstyrrelse hos en person udvalgt fra gruppen bestående af akut koronart syndrom, indbefattende akut myokardieinfarkt (AMI) og angina, hjerteinsufficiens, vulnerable plaques og karsygdom, indbefattende atherosklerose, eller til forudsigelse, diagnosticering eller monitorering af en akut og/eller kronisk nyresygdom, -læsion eller -forstyrrelse hos en person, hvilken fremgangsmåde omfatter: (a) måling af niveauet af CNPsp-fragmentet ifølge SEQ ID NO: 6 i en biologisk prøve fra personen; og (b) sammenligning af niveauet af CNPsp-fragmentet med niveauet fra en kontrol, hvor et målt niveau af CNPsp-fragmentet, der er større end kontrolniveauet, indikerer hjerteforstyrrelsen eller nyresygdommen, -læsionen eller -forstyrrelsen.
2. Fremgangsmåde ifølge krav 1, hvor fremgangsmåden anvendes til at evaluere eller monitorere et respons på behandling af en akut eller kronisk hj erteforstyrrelse hos en person, eller til at evaluere eller monitorere et respons på behandling af en akut eller kronisk nyresygdom eller -forstyrrelse hos en person, hvor en ændring i det målte niveau af CNPsp-fragmentet i forhold til kontrolniveauet indikerer et respons på behandlingen.
3. Fremgangsmåde ifølge krav 1, hvilken fremgangsmåde omfatter: (i) måling af niveauet af CNPsp-fragmentet i en biologisk prøve fra personen inden for de første 48 timer, 24 timer, 12 timer, seks timer, fire timer, to timer, én time eller 30 minutter efter indtræden af, eller klinisk præsentation med hjerteforstyrrelsen eller nyreforstyrrelsen eller -sygdommen.
4. Fremgangsmåde ifølge krav 1 eller 3, hvor: (i) et niveau af CNPsp-fragmentet deraf i prøven inden for intervallet 40 til 250 pmol/L, 65 til 200 pmol/L, 70 til 150 eller 70 til 130 pmoFL, indikerer et AKS; og/eller (ii) et niveau af CNPsp-fragmentet deraf i prøven der er 1,5 til 10, 1,5 til 5, eller 2 til 3 gange større end kontrolniveauet, indikerer indtræden af et AKS; og/eller (iii) den akutte hjerteforstyrrelse er et akut myokardieinfarkt (AMI) med ST-elevation på EKG, ustabilt angina, et akut ikke ST-eleveret myokardieinfarkt; hjerteiskæmi, akut hjerte læsion, akut hjerteskade som følge af akut lægemiddelforgiftning eller et akut kardiomyopati.
5. Fremgangsmåde ifølge et hvilket som helst af de foregående krav: (i) hvor den biologiske prøve er en blod-, veneblod-, arterieblod-, plasma-, serum-, spyt-, interstitielvæske, urin- eller hjertevævsprøve; og/eller niveauet af CNPsp-fragmentet måles ved anvendelse af et assay udvalgt fra massespektroskopi (indbefattende SELDI, ESI, MALDI eller FTIC), RIA, ELISA, fluoroimmunoassay, immunofluorometrisk assay og immunoradiometrisk assay.
6. Fremgangsmåde ifølge et hvilket som helst af de foregående krav, der endvidere omfatter måling af niveauet af én eller flere ikke-CNPsp-markører af AKS, og sammenligning af niveauerne med markømiveauer fra en kontrol, hvor en afvigelse i det målte niveau i forhold til kontrolniveauet, sammen med et målt niveau af CNPsp-fragmentet, der er større end kontrolniveauet af CNPsp-fragmentet, forudsiger eller diagnosticerer AKS, eller kan anvendes til at monitorere AKS, og hvor ikke-CNPsp-markøren er udvalgt fra gruppen bestående af troponin T, troponin I, creatinkinase-MB, myoglobin, ANP, ANP-SP, BNP, NT-BNP, BNP-SP, LDH, aspartataminotransferase, H-FABP, iskæmimodificeret albumin, endothelin, adrenomedullin, renin og angiotensin II.
7. Anvendelse af et antistof eller en antigenbindende del deraf, der specifikt eller selektivt binder til CNPsp-fragmentet ifølge SEQ ID NO: 6 i et assay til vurdering af en biologisk event eller forstyrrelse udført på en biologisk prøve fra en person; hvor den biologiske event eller forstyrrelse er AKS eller en nyreforstyrrelse.
8. Anvendelse ifølge krav 7, hvor antistoffet eller antigenbindende fragment deraf er et polyklonalt, monoklonalt, kimærisk eller humaniseret antistof eller det antigenbindende fragment deraf, og/eller hvor antistoffet eller det antigenbindende fragment deraf er mærket med en detekterbar markør.
9. Antistof eller antigenbindende del deraf, der selektivt eller specifikt binder til CNPsp-fragmentet ifølge SEQ ID NO: 6.
10. Antistof eller antigenbindende fragment deraf ifølge krav 9, der er et polyklonalt, monoklonalt, kimærisk eller humaniseret antistof eller antigenbindende fragment deraf, og/eller der er mærket med en detekterbar markør.
11. Isoleret peptid, der er CNPsp-fragmentet ifølge SEQ ID NO: 6.
12. Anvendelse af et peptid ifølge krav 11 i fremstillingen af et antistof.
13. Assay til et peptid ifølge krav 11 i en biologisk prøve fra en person, hvilket assay omfatter etablering af kontakt mellem prøven og et antistof eller antigenbindende del deraf ifølge lerav 9 eller 10, og detektering og måling af niveauet af peptidet i prøven anvendelse af en hvilken som helst kendt fremgangsmåde.
14. Assay ifølge krav 13 hvor: (i) den biologiske prøve er en prøve fra blod, veneblod, arterieblod, plasma, serum, spyt, interstitielvæske, urin, en hjerte vævsprøve eller nyrevævsprøve; (ii) niveauet af peptidet måles ved anvendelse af massespektroskopi, eller (iii) niveauet af peptidet måles ved anvendelse af et assay udvalgt fra RIA, ELISA, immunofluorometrisk assay og immunoradiometrisk assay.
15. Kit til forudsigelse, diagnosticering eller monitorering af en akut hjerteforstyrrelse, omfattende et antistof eller en antigenbindende del deraf ifølge krav 9; og eventuelt omfattende instruktioner til forudsigelse, diagnosticering eller monitorering af den akutte hjerteforstyrrelse hos en person inden seks til fire timer fra indtræden, eller klinisk præsentation, fra niveauet af et CNPsp-, eller CNPsp-fragment deraf, målt i en biologisk prøve, der er opnået inden seks eller fire timer fra indtræden, eller klinisk præsentation med AKS, og eventuelt hvor kittet er kalibreret til at måle niveauer af CNPsp, eller CNPsp-fragment deraf, inden for intervallet fra 0,1 til 1500 pmol/L, 0,1 til 350 pmol/L, 1 til 300 pmol/L, 10 til 250 eller 20 til 150 pmol/L.
DK11810311.8T 2010-07-19 2011-07-19 Signalbiomarkører DK2596010T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36567710P 2010-07-19 2010-07-19
PCT/US2011/044586 WO2012012469A2 (en) 2010-07-19 2011-07-19 Signal biomarkers

Publications (1)

Publication Number Publication Date
DK2596010T3 true DK2596010T3 (da) 2017-07-31

Family

ID=45497426

Family Applications (1)

Application Number Title Priority Date Filing Date
DK11810311.8T DK2596010T3 (da) 2010-07-19 2011-07-19 Signalbiomarkører

Country Status (10)

Country Link
US (3) US9103840B2 (da)
EP (2) EP2596010B1 (da)
JP (2) JP6087816B2 (da)
CN (1) CN103140498B (da)
AU (2) AU2011282245B2 (da)
CA (1) CA2805794A1 (da)
DK (1) DK2596010T3 (da)
ES (1) ES2629850T3 (da)
NZ (2) NZ605640A (da)
WO (1) WO2012012469A2 (da)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2596010T3 (da) * 2010-07-19 2017-07-31 Otago Innovation Ltd Signalbiomarkører
CN102608335A (zh) * 2012-04-19 2012-07-25 协和生物制药（天津）有限公司 NT-proBNP时间分辨荧光免疫分析试剂盒的制备方法
HUE069048T2 (hu) * 2015-01-09 2025-02-28 Global Genomics Group Llc Vér alapú biomarkerek ateroszklerotikus koszorúér-betegség diagnosztizálására
CN106706623A (zh) * 2016-12-30 2017-05-24 广州华弘生物科技有限公司 一种快速检测缺血修饰白蛋白的试剂盒及其应用
US20220155322A1 (en) * 2019-03-15 2022-05-19 Mayo Foundation For Medical Education And Research Use of natriuretic peptides to assess and treat acute kidney injury
PL444560A1 (pl) * 2023-04-25 2024-10-28 Uniwersytet Medyczny W Białymstoku Zastosowanie biomarkera IMA

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4196265A (en) 1977-06-15 1980-04-01 The Wistar Institute Method of producing antibodies
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5310687A (en) 1984-10-31 1994-05-10 Igen, Inc. Luminescent metal chelate labels and means for detection
GB8800077D0 (en) 1988-01-05 1988-02-10 Ciba Geigy Ag Novel chimeric antibodies
US5843708A (en) 1988-01-05 1998-12-01 Ciba-Geigy Corporation Chimeric antibodies
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5939272A (en) 1989-01-10 1999-08-17 Biosite Diagnostics Incorporated Non-competitive threshold ligand-receptor assays
US5028535A (en) 1989-01-10 1991-07-02 Biosite Diagnostics, Inc. Threshold ligand-receptor assay
US5744101A (en) 1989-06-07 1998-04-28 Affymax Technologies N.V. Photolabile nucleoside protecting groups
US5922615A (en) 1990-03-12 1999-07-13 Biosite Diagnostics Incorporated Assay devices comprising a porous capture membrane in fluid-withdrawing contact with a nonabsorbent capillary network
WO1991017440A1 (en) 1990-05-07 1991-11-14 Immunomedics, Inc. Improved method for radiolabeling monovalent antibody fragments
CA2072758A1 (en) 1990-09-14 1992-03-15 Kenneth Francis Buechler Antibodies to complexes of ligand receptors and ligands and their utility in ligand-receptor assays
CA2095633C (en) 1990-12-03 2003-02-04 Lisa J. Garrard Enrichment method for variant proteins with altered binding properties
US5221685A (en) 1991-02-01 1993-06-22 Ube Industries, Ltd. Thiazoline derivative, process for preparing the same and chemical for controlling noxious organisms containing the same
US5955377A (en) 1991-02-11 1999-09-21 Biostar, Inc. Methods and kits for the amplification of thin film based assays
CA2107894C (en) 1991-04-10 2003-10-14 Kenneth F. Buechler Crosstalk inhibitors and their uses
EP0579767B1 (en) 1991-04-11 2000-08-23 Biosite Diagnostics Inc. Novel conjugates and assays for simultaneous detection of multiple ligands
US6143576A (en) 1992-05-21 2000-11-07 Biosite Diagnostics, Inc. Non-porous diagnostic devices for the controlled movement of reagents
US6019944A (en) 1992-05-21 2000-02-01 Biosite Diagnostics, Inc. Diagnostic devices and apparatus for the controlled movement of reagents without membranes
US5494829A (en) 1992-07-31 1996-02-27 Biostar, Inc. Devices and methods for detection of an analyte based upon light interference
US5605798A (en) 1993-01-07 1997-02-25 Sequenom, Inc. DNA diagnostic based on mass spectrometry
EP0700521B1 (en) 1993-05-28 2003-06-04 Baylor College Of Medicine Method and mass spectrometer for desorption and ionization of analytes
US5824799A (en) 1993-09-24 1998-10-20 Biosite Diagnostics Incorporated Hybrid phthalocyanine derivatives and their uses
ATE224053T1 (de) 1993-11-12 2002-09-15 Inverness Medical Switzerland Vorrichtung zum ablesen von teststreifen
ES2145034T3 (es) 1993-11-12 2000-07-01 Unilever Nv Dispositivos analiticos y procedimientos para el uso de los mismos.
US5647124A (en) 1994-04-25 1997-07-15 Texas Instruments Incorporated Method of attachment of a semiconductor slotted lead to a substrate
GB9419267D0 (en) 1994-09-23 1994-11-09 Unilever Plc Assay devices
US5792294A (en) 1995-11-16 1998-08-11 Otis Elevator Company Method of replacing sheave liner
US5719600A (en) 1995-12-12 1998-02-17 Hewlett-Packard Company Gradient calculation system and method
US6113855A (en) 1996-11-15 2000-09-05 Biosite Diagnostics, Inc. Devices comprising multiple capillarity inducing surfaces
US5947124A (en) 1997-03-11 1999-09-07 Biosite Diagnostics Incorporated Diagnostic for determining the time of a heart attack
US6057098A (en) 1997-04-04 2000-05-02 Biosite Diagnostics, Inc. Polyvalent display libraries
NZ516848A (en) 1997-06-20 2004-03-26 Ciphergen Biosystems Inc Retentate chromatography apparatus with applications in biology and medicine
GB9717926D0 (en) 1997-08-22 1997-10-29 Micromass Ltd Methods and apparatus for tandem mass spectrometry
JP2002502086A (ja) 1998-01-23 2002-01-22 アナリティカ オブ ブランフォード インコーポレーテッド 表面からの質量分光測定
US6150098A (en) * 1998-02-20 2000-11-21 Amgen Inc. Methods for identifying novel secreted mammalian polypeptides
US6406921B1 (en) 1998-07-14 2002-06-18 Zyomyx, Incorporated Protein arrays for high-throughput screening
US6831060B2 (en) 1999-05-07 2004-12-14 Genentech, Inc. Chimpanzee erythropoietin (CHEPO) polypeptides and nucleic acids encoding the same
US6784154B2 (en) 2001-11-01 2004-08-31 University Of Utah Research Foundation Method of use of erythropoietin to treat ischemic acute renal failure
AU2002366875B2 (en) 2001-12-21 2008-08-21 Sense Proteomic Limited Probe for mass spectrometry
AUPS169202A0 (en) 2002-04-11 2002-05-16 Goetze, Jens Peter Neuropeptide assay
US6780645B2 (en) 2002-08-21 2004-08-24 Lifescan, Inc. Diagnostic kit with a memory storing test strip calibration codes and related methods
US7045366B2 (en) 2003-09-12 2006-05-16 Ciphergen Biosystems, Inc. Photocrosslinked hydrogel blend surface coatings
US20040091961A1 (en) * 2002-11-08 2004-05-13 Evans Glen A. Enhanced variants of erythropoietin and methods of use
US7341838B2 (en) 2003-04-17 2008-03-11 Biosite Incorporated Polypeptides related to natriuretic peptides and methods of their identification and use
US20060216757A1 (en) * 2003-04-25 2006-09-28 The Kenneth S. Warren Institute, Inc. Tissue protective cytokine receptor complex, assays for identifying tissue protective compounds and uses thereof
US7718363B2 (en) * 2003-04-25 2010-05-18 The Kenneth S. Warren Institute, Inc. Tissue protective cytokine receptor complex and assays for identifying tissue protective compounds
JP2008500949A (ja) 2003-07-02 2008-01-17 ジェネンテック・インコーポレーテッド 腫瘍の診断と治療のための組成物と方法
WO2005052593A1 (en) * 2003-10-29 2005-06-09 The University Of Leicester Detection
US7423139B2 (en) 2004-01-20 2008-09-09 Insight Biopharmaceuticals Ltd. High level expression of recombinant human erythropoietin having a modified 5′-UTR
CN101039953B (zh) 2004-07-23 2012-08-15 沃尔特及伊莱萨霍尔医学研究院 治疗和诊断剂
CA2575402A1 (en) 2004-08-05 2006-02-09 Genentech, Inc. Humanized anti-cmet antagonists
JP2006292623A (ja) 2005-04-13 2006-10-26 Univ Of Dundee 心不全における突然死のマーカー
EP1731910A1 (en) 2005-06-07 2006-12-13 F. Hoffmann-La Roche Ag Use of NT-proANP and NT-proBNP for diagnosing cardiac diseases
EP1746161A1 (en) * 2005-07-20 2007-01-24 Cytheris Glycosylated IL-7, preparation and uses
WO2008030122A1 (en) 2006-09-07 2008-03-13 University Of Otago Biomarkers
US9086408B2 (en) * 2007-04-30 2015-07-21 Nexus Dx, Inc. Multianalyte assay
GB0712670D0 (en) 2007-06-29 2007-08-08 King S College London Isolated peptides and uses thereof
CN101878224A (zh) * 2007-08-03 2010-11-03 埃斯特瑞恩有限公司 促红细胞生成素融合蛋白
WO2009104974A2 (en) * 2008-02-22 2009-08-27 Christopher Joseph Pemberton Biomarkers
JP2011516038A (ja) 2008-03-12 2011-05-26 オタゴ イノベーション リミテッド バイオマーカー
DK2596010T3 (da) * 2010-07-19 2017-07-31 Otago Innovation Ltd Signalbiomarkører

Also Published As

Publication number Publication date
JP2013532820A (ja) 2013-08-19
US20190100576A1 (en) 2019-04-04
US9994631B2 (en) 2018-06-12
CN103140498A (zh) 2013-06-05
CA2805794A1 (en) 2012-01-26
WO2012012469A3 (en) 2012-05-18
WO2012012469A2 (en) 2012-01-26
NZ707637A (en) 2016-09-30
JP2017122093A (ja) 2017-07-13
EP2596010A4 (en) 2013-11-13
NZ605640A (en) 2016-01-29
AU2017235947A1 (en) 2017-10-26
EP2596010A2 (en) 2013-05-29
EP3246335A2 (en) 2017-11-22
EP2596010B1 (en) 2017-04-12
CN103140498B (zh) 2017-05-17
US20120045780A1 (en) 2012-02-23
JP6087816B2 (ja) 2017-03-01
AU2011282245A1 (en) 2013-02-28
AU2011282245B2 (en) 2017-09-28
EP3246335A3 (en) 2017-12-27
ES2629850T3 (es) 2017-08-16
US20150353632A1 (en) 2015-12-10
US9103840B2 (en) 2015-08-11

Similar Documents

Publication Publication Date Title
US20190100576A1 (en) Signal biomarkers
US9151766B2 (en) Methods of determination of activation or inactivation of atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP) hormonal systems
US8507209B2 (en) Biomarkers
DK2828282T3 (da) Biomarkører
US10106575B2 (en) Biomarkers
US20180156822A1 (en) Biomarker for cardiac disorders
CA2771954A1 (en) Pneumonia biomarkers
JP4423426B2 (ja) アドレノメデュリン前駆体ｃ末端ペプチドの濃度の上昇を循環器疾患又は炎症性疾患の指標とする方法